Skip to main content
profile image
Selected Works of Dave S.B. Hoon, PhD
Article
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition
Proceedings of the National Academy of Sciences of the United States of America (2013)
  • Rizwan Haq, Boston University
  • Satoru Yokoyama, University of Toyama
  • Elena B. Hawryluk, Lund University
  • Göran B. Jönsson, Lund University
  • Dennie Tompers Frederick, Harvard University
  • Kevin McHenry, Novartis
  • Dale Porter, Novartis
  • Thanh Nga Tran, Dermatology and Cutaneous Biology Research Center
  • Kevin T. Love, Massachusetts Institute of Technology
  • Robert Langer, Massachusetts Institute of Technology
  • Daniel G. Anderson, Massachusetts Institute of Technology
  • Levi A. Garraway, Broad Institute
  • Lyn Mc Divitt Duncan, Harvard University
  • Donald L. Morton, John Wayne Cancer Institute
  • Dave S.B. Hoon
  • Jennifer A. Wargo, Surgical Oncology
  • Jun S. Song, University of California, San Francisco
  • David E. Fisher, Boston University
Link
Disciplines
Publication Date
March 12, 2013
DOI
10.1073/pnas.1205575110
Citation Information
Rizwan Haq, Satoru Yokoyama, Elena B. Hawryluk, Göran B. Jönsson, et al.. "BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition" Proceedings of the National Academy of Sciences of the United States of America Vol. 110 Iss. 11 (2013) p. 4321 - 4326
Available at: http://works.bepress.com/dave-hoon/118/